Chlorine Dioxide against Hepatitis B Virus: What the 2026 Evidence Shows
Laboratory evidence, product-specific claims and PT2 use are different questions. A source-led review of the Japanese Journal of Infectious Diseases study.
A 2026 Japanese Journal of Infectious Diseases paper by Chen and colleagues examined chlorine dioxide against hepatitis B virus (HBV) in a laboratory infection system. It found concentration-dependent reductions in infection-related markers under the tested conditions. The chlorine dioxide preparation was supplied by Taiko Pharmaceutical, not ChloroKlean. This article explains the evidence and its limits; it does not establish a ChloroKlean HBV claim, a surface-disinfection protocol or a treatment for hepatitis B.
The primary study and the question it asked
Evaluation of the Virucidal Activity of Chlorine Dioxide against Hepatitis B Virus was published online on 31 August 2026 as an advance publication (Chen, Pereira, Watashi, Shibata and Miura; doi 10.7883/yoken.JJID.2026.047). The authors compared chlorine dioxide (ClO₂) with sodium hypochlorite (NaClO) over a matched experimental concentration range. These are different disinfectants; a result for one must not be attributed to the other.
The purpose was to compare relative activity in a defined in vitro system, not to validate recommended use concentrations. The full manuscript, rather than the abstract alone, is important because it identifies the commercial preparation, control experiments, surrogate endpoints and company relationships.
What was tested and measured
The researchers used laboratory-produced HBV genotype D and HepG2-hNTCP-C4 cells, a human liver tumour-derived cell line engineered to support HBV infection. Virus was exposed to the test chemicals in liquid, residual disinfectant was neutralised with sodium thiosulfate, and the treated virus was then used to infect the cells. This was not a test of dried blood on a hospital surface, a commercial cleaning programme or a swimming pool.
The study measured released hepatitis B surface antigen (HBsAg), hepatitis B core antigen-positive cells, intracellular HBV RNA and extracellular HBV DNA after infection. These are infection-related surrogate markers, not interchangeable measures of infectious virus. In particular, extracellular DNA does not directly quantify infectious virions. Neutraliser, cell-permissiveness and ultrafiltration controls supported an effect on the virus rather than simply a carry-over effect on the cell assay.
The authors also tested a defined organic challenge containing bovine serum albumin and sheep erythrocytes. That model does not represent every blood spill, soil load or clinical surface. The preparation identified in the methods is Cleverin from Taiko Pharmaceutical; ChloroKlean was not tested.
What the results support
Across the measured endpoints, chlorine dioxide pretreatment reduced subsequent infection-related signals as the experimental concentration increased. Sodium hypochlorite produced smaller reductions at matched concentrations in these experiments. This is a within-study comparison, not a basis for ranking the disinfectants at their respective practical use conditions.
The authors did not observe a statistically significant loss of chlorine dioxide activity under their defined organic challenge. That does not establish that organic matter has no effect in practice. Organic demand, surface conditions, formulation and cleaning still need to be assessed for the intended use.
Reduced marker signals are not evidence of complete HBV elimination or a specified virucidal log reduction on surfaces. The paper discusses a possible effect on viral entry proteins, but the proposed molecular explanation requires direct confirmation.
What the study does not establish
Only one HBV genotype, laboratory-produced virus and a tumour-derived cell infection model were used. The authors call for work with other genotypes, patient-derived virus, primary human hepatocytes and infectivity-titration methods. The findings therefore remain bounded by that laboratory model.
The paper does not validate a clinical or field disinfection process, a particular surface or material, occupational exposure safety, or an HBV claim for any ChloroKlean product. It does not justify replacing an established sodium hypochlorite protocol. A matched laboratory comparison is not a comparison of fully validated, labelled use patterns.
This guide deliberately does not reproduce the experimental concentrations as operating targets. Neither those concentrations nor the experimental contact times are ChloroKlean product directions. Do not use the study to select a dose, dilute a product, treat drinking water, or treat a person. Healthcare exposure and infection-control decisions belong with the relevant clinical and occupational-health procedures.
PT2 relevance and GB BPR evidence
PT2 includes disinfection of relevant surfaces, materials and equipment not used for direct contact with food or feed, and other specified non-drinking-water uses. An HBV surface-disinfection question can therefore be relevant to PT2, but PT2 coverage alone does not establish a virucidal claim, a healthcare use or permission for every application. Products applied directly to people, drinking-water treatment (PT5), food/feed-area uses (PT4), veterinary hygiene (PT3) and medical-device disinfection require their own applicable classification and legal assessment.
For a Great Britain use, verify the exact product and intended claim, the applicable authorisation or lawful transitional route, precursor-route/product-type status, GB Article 95 supply chain and label. Article 95 listing is not an efficacy assessment or product authorisation. A published study on another supplier's preparation cannot substitute for evidence supporting the product actually supplied.
ChloroKlean's stated Great Britain supply position is under applicable GB BPR transitional arrangements, not a claim of full product authorisation. This page adds no HBV indication and claims no EU or Northern Ireland authorisation. The linked GB BPR evidence guide explains why scientific findings, label claims and advertising requirements must be assessed separately.
Commercial relationships and source transparency
The manuscript lists Taiko Pharmaceutical R&D affiliations for Chen, Pereira, Shibata and Miura. Its conflict-of-interest statement identifies Chen, Pereira and Shibata as employees and Miura as a research advisor receiving consulting fees from Taiko. Watashi is affiliated with Japan's National Institute of Infectious Diseases, Japan Institute for Health Security. The paper does not provide a separate grant-funding statement.
These relationships are relevant context because Taiko supplied the chlorine dioxide preparation. They do not by themselves invalidate the experiments, but the study should not be described as independent testing of ChloroKlean. The primary publication and full manuscript are linked in the visible references below.
Assessing an HBV disinfection claim
An evidence-review sequence, not a cleaning or dosing protocol.
Define the intended use
Identify the surface, contamination, users and relevant legal regime; do not infer coverage from PT2 alone.
Read the primary evidence
Check the formulation, organism, matrix, endpoints, controls and disclosures.
Verify the product-specific basis
Check lawful GB BPR supply and evidence for the exact product, claim and label conditions.
Follow the appropriate procedure
Use the approved site infection-control procedure and product label, not experimental study concentrations.
Expert Insights
About the Reviewer
Gavin Owen
Managing Director, ChloroKlean
Gavin Owen leads ChloroKlean's technical and commercial operations, bringing over 20 years of experience in industrial chemical distribution and water treatment. He oversees product development, regulatory compliance strategy, and the company's BPR compliance programme across PT2, PT4, PT5, and PT11 product types. Gavin works directly with water treatment professionals, facilities managers, and public health engineers across healthcare, leisure, food processing, and industrial sectors.
Frequently Asked Questions
Common questions about this topic, answered by our technical team.
Evidence is not a product instruction
- This is an educational review, not medical advice, a blood-spill procedure or a product dosing instruction.
- Use biocides safely. Always read the label and product information before use.
- Follow the relevant infection-control procedure, risk assessment and Safety Data Sheet; do not replace them with laboratory conditions.
Generic chlorine dioxide research and results for another supplier's preparation do not establish ChloroKlean efficacy, an HBV claim or an authorised use.
Related Resources
Continue exploring our knowledge base and product information.
PT2 disinfectants explained
Understand the boundaries of PT2 rather than inferring a pathogen claim.
PT2 product and application information
Separate pool and spa uses from the laboratory HBV evidence reviewed here.
GB BPR efficacy claims and advertising
Why product claims require evidence for the stated use.
GB BPR compliance and product status
Check authorisation or applicable transitional supply, not Article 95 alone.
Sources & References
This article references guidance from the following authoritative sources:
- Evaluation of the Virucidal Activity of Chlorine Dioxide against Hepatitis B Virus (31 August 2026)
Industry Standard - Chen et al., Japanese Journal of Infectious Diseases, advance publication
- Full accepted manuscript: methods, results and conflict-of-interest statement
Industry Standard - Japanese Journal of Infectious Diseases / J-STAGE
- Efficacy: information requirements
HSE - Health and Safety Executive
- Efficacy: assessment and evaluation
HSE - Health and Safety Executive
- Advertising requirements for biocidal products
HSE - Health and Safety Executive
External links open in a new window. ChloroKlean is not responsible for the content of external websites.